3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
21
Ovarian Neoplasms
18
Lung Neoplasms
14
Breast Neoplasms
13
Endometrial Neoplasms
12
Fallopian Tube Neoplasms
11
Parkinson Disease 4, Autosomal Dominant Lewy Body
10
Neoplasm Metastasis
10
Squamous Cell Carcinoma of Head and Neck
7
Triple Negative Breast Neoplasms
5
Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Carcinoma
4
Adenocarcinoma Of Esophagus
4
Stomach Neoplasms
3
Melanoma
3
Colorectal Neoplasms
3
Adenocarcinoma
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Small Cell Lung Carcinoma
2
Peritoneal Neoplasms
2
HER2-positive Breast Cancer
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Brenner Tumor
2
Advanced Solid Tumour
2
Adenocarcinoma, Bronchiolo-Alveolar
2
Interventions
pembrolizumab
1
Paclitaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Non-small Cell Lung Cancer
×
Paclitaxel
×
30 days
×
Clear all
NCT07221474
2026-06-09
INTerpath-13
Merck Sharp & Dohme LLC
Phase 2
Recruiting
180 enrolled